![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
Par Pharmaceutical, Inc. Algorithme Pharma Inc |
---|---|
Information provided by: | Par Pharmaceutical, Inc. |
ClinicalTrials.gov Identifier: | NCT00653458 |
To compare the single-dose bioavailability of Ondansetron ODT 8 mg and Zofran 8 mg
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: Ondansetron Drug: Zofran |
Phase I |
Study Type: | Interventional |
Study Design: | Randomized, Open Label, Crossover Assignment |
Official Title: | Comparative, Randomized, Single-Dose, Cross Over Bioavailability Study of Kali's Ondansetron ODT 8 mg With That of GlaxoSmithKine's Zofran ODT 8 mg in Healthy Adult Subjects Under Fed Conditions |
Enrollment: | 18 |
Study Start Date: | August 2002 |
Study Completion Date: | September 2002 |
Primary Completion Date: | September 2002 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
Subjects received Kali formulated products under fed conditions
|
Drug: Ondansetron
ODT, 8 mg, single-dose, fed conditions
|
B: Active Comparator
Subjects received GlaxoSmithKline's formulated products under fed conditions
|
Drug: Zofran
ODT, 8 mg, single-dose, under fed conditions
|
To compare the single-dose bioavailability of Kali's Ondansetron ODt 8 mg with that of GlaxoSmithKine's Zofran 8 mg under fed conditions
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Par Pharmaceutical, Inc. ( Dr.Alfred Elvin/ Diector Biopharmaceutics ) |
Study ID Numbers: | ODO-P2-159 |
Study First Received: | April 4, 2008 |
Last Updated: | April 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00653458 |
Health Authority: | United States: Institutional Review Board |
bioequivalence Ondansetron ODT fed To determine bioequivalence under fed conditions |
Malnutrition Ondansetron Healthy Serotonin |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Gastrointestinal Agents Central Nervous System Depressants Antiemetics Antipsychotic Agents Pharmacologic Actions |
Serotonin Antagonists Serotonin Agents Autonomic Agents Therapeutic Uses Antipruritics Anti-Anxiety Agents Peripheral Nervous System Agents Central Nervous System Agents Dermatologic Agents |